Goldman Sachs Maintains Buy on Blueprint Medicines, Lowers Price Target to $83
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Terence Flynn maintains a Buy rating on Blueprint Medicines (NASDAQ:BPMC) but has lowered the price target from $93 to $83.

August 04, 2023 | 1:21 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs maintains a Buy rating on Blueprint Medicines but lowers the price target from $93 to $83.
The news is directly related to Blueprint Medicines. While the Buy rating is maintained, the lowering of the price target could indicate a potential decrease in the short-term performance of the stock. However, the impact is not necessarily negative as the Buy rating is still in place.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100